The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2025 | Challenges in developing ADCs for pancreatic ductal adenocarcinoma
James Harding, MD, Memorial Sloan Kettering Cancer Center, New York, NY, comments on the emergence of antibody drug conjugates (ADCs) for pancreatic ductal adenocarcinoma, which will compete with the currently used RAS inhibitors in this space. While RAS inhibition shows promise, resistance to current therapies may still occur, making it reasonable to continue targeting MET in these patient populations. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So we’ve seen a number of antibody drug conjugates come into play for pancreatic ductal carcinoma. Of course, I think the largest challenge is the fact that we are seeing so many RAS inhibitors enter this space. And the preliminary data is that RAS inhibition seems to be compelling and so ADCs will have to exist in that space. I think this is still quite reasonable though given the fact that resistance occurs with precision medicine and there may be some rationale for continuing to target MET in these patient populations...
So we’ve seen a number of antibody drug conjugates come into play for pancreatic ductal carcinoma. Of course, I think the largest challenge is the fact that we are seeing so many RAS inhibitors enter this space. And the preliminary data is that RAS inhibition seems to be compelling and so ADCs will have to exist in that space. I think this is still quite reasonable though given the fact that resistance occurs with precision medicine and there may be some rationale for continuing to target MET in these patient populations. So this is, I think, very important.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
